A Phase 1/2a Blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, and Dose-range Finding of Multiple Ascending Doses of ISIS 598769 Administered Subcutaneously to Adult Patients With Myotonic Dystrophy Type 1
Phase of Trial: Phase I/II
Latest Information Update: 09 Nov 2016
At a glance
- Drugs Baliforsen (Primary)
- Indications Myotonic dystrophy
- Focus Adverse reactions
- Sponsors Ionis Pharmaceuticals
- 02 Nov 2016 Status changed from active, no longer recruiting to completed.
- 16 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology